Module 3: (Part 1) Immune Assessment of Immunomodulatory Biotherapeutics and (Part 2) Approaches to MABEL Starting Dose Selection
Recorded On: 05/04/2023
Part 1: Immune Assessment of Immunomodulatory Biotherapeutics
In Part 1 of this module, we will review both in vitro and in vivo models to characterize the immunopharmacology and assess the safety risks of immunomodulatory biotherapeutics. The mechanisms of cytokine release, immune cell activation/modulation, antibody-dependent cell cytotoxicity (ADCC), antibody-dependent cell phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and other immunological activities will be reviewed. The use of in vitro assays to assess these activities, as well as in vivo animal models incorporating blood and tissue immune cell immunophenotyping by flow cytometry, quantification of cytokines/chemokines, complement components, and acute phase reactants, and assessing immune function endpoints to characterize these immunological activities of biotherapeutics will be discussed. The requirement for such assays and key considerations for study design (e.g., for cytokine release assays (CRAs), whether PBMCs or whole blood, or soluble or immobilized drug should be used) will be discussed, and decision trees, based on drug structure, mechanism of action, and other risk factors, will be reviewed. Gaps in translation of these models to humans will be discussed, and suggestions to fill these gaps proposed. How these immunopharmacology/immunosafety data are considered with other data in the selection of a First-In-Human starting dose and in clinical risk mitigation and risk management will also be considered in the context of short case studies.
Part 2: Approaches to MABEL Starting Dose Selection
Dose selection for first-in-human clinical trials with immune agonist biologics should be based on thoughtfully designed nonclinical pharmacology and toxicology studies, ex vivo/in vitro studies with human and animal cells, and pharmacokinetic/pharmacodynamic (PK/PD) modeling approaches. This approach requires a thorough understanding of the biology of the target and the relative binding and pharmacological activity of the molecule in animals and humans. Due to severe adverse events observed with Tegenero (an anti-CD28 superagonist mAb (TGN1412)) in 2006, choosing a safe starting dose and dose escalation for human trials with immune agonist biologics has been a focus of biotech companies as well as worldwide health authorities. With the increase in immune-oncology target identification and drug development in recent years, it is important to understand MABEL and the integrated data approach to setting the clinical starting dose. This presentation will discuss the importance of designing appropriate nonclinical pharmacology and toxicology studies, as well as ex vivo/in vitro studies with human and animal cells, to enable effective pharmacokinetic/ pharmacodynamic (PK/PD) modeling and clinical starting dose selection. Examples of successful starting dose approaches using a MABEL approach will also be presented.
Sanela Bilic, PharmD, MBA
Senior Director of Clinical Pharmacology
D3 Medicine
Dr. Sanela Bilic is a highly respected professional with proven leadership skills and 18 years of broad experience within pharmaceutical drug development. She has extensive hands-on experience with all phases of drug development globally. Dr. Bilic possesses broad knowledge of drug development principles and practice ranging from target identification to early proof of concept, to tox interrogation, to IND, to early clinical development, and to mature development of small and large molecules. She is especially focused on the development of immuno-oncology therapeutics and ADCs. Dr. Bilic has also guided teams through the development of CAR T-cell, armed T-cell, and NK-cell therapies. In addition, she has extensive regulatory interaction experience with all major global health authorities.
After obtaining a Doctorate in Pharmacy and an MBA, Dr. Bilic completed a 2-year fellowship in Drug Development from SUNY at Buffalo and Novartis Pharmaceuticals in Oncology. She started her professional life in the Oncology clinical pharmacology department at Novartis. Following Dr. Bilic’s exponential professional as well as personal growth with Novartis, she joined D3 Medicine (now Certara) as a Senior Director, Clinical Pharmacology. During her years at Novartis and Certara (D3 Medicine), Dr. Bilic was an integral part of the development team with extensive experience as the clinical pharmacology representative for global regulatory authority interactions. Dr. Bilic has worked as a clinical pharmacology leader between research and early development, early development, and late development, and has led due diligence efforts from a clinical pharmacology perspective to aid in thorough assessment of business development opportunities. Dr. Bilic has led the clinical pharmacology strategic development of numerous assets from preclinical development/research stage to the end of Phase 2 and beyond. She uses a unique problem-solving approach, applied in Pharma and with global regulatory agencies (FDA, EMEA, PMDA), resulting in a high rate of successful solutions. She has a track record of anticipating problems and resolving them early and is responsible for nonclinical and/or clinical PK sections of over 50+ pre-INDs, INDs, and IMPDs.
Frank Brennan, PhD
Executive Director of Preclinical Safety
Novartis Institutes for Biomedical Research
Dr. Frank Brennan is currently an Executive Director in the Department of Preclinical Safety (PCS) at the Novartis Institutes for Biomedical Research in Cambridge, Massachusetts (but working from his UK home). Dr. Brennan works across the Novartis Biologics Portfolio, with a focus on ImmunoOncology. He has over 30 years’ experience in immunology, immunotoxicology, immunogenicity, and safety assessment of biologics in academia, the CRO Industry (HLS, now Labcorp, UK), small biotechnology companies, mid-size Pharma (Novo Nordisk, UCB), and large Pharma (AstraZeneca and Novartis). This work has led to over 75 publications in peer-reviewed journals and books. Dr. Brennan is a former Chair of the Biotechnology Innovation Organization (BIOsafe) Leadership Committee and is currently an active member of several external industry and academic initiatives and consortia. Dr. Brennan has a Bachelor of Science Degree in Immunology from the University of Glasgow (Scotland), a PhD in Immunology and Microbiology from the University of Edinburgh (Scotland), and held a Postdoctoral position in Immunology/Rheumatology at Rush Medical Center in Chicago.